Cars.com
CARS
Lantheus
LNTH
Halozyme Therapeutics
HALO
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
Collegium Pharmaceutical
COLL
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 251.74%224.16M | -50.75%55.72M | 132.87%97.45M | 118.21%61.3M | -71.36%9.7M | -153.15%-147.73M | 10.99%113.12M | -38.26%41.85M | -677.42%-336.58M | -32.21%33.87M |
Net income from continuing operations | -13.58%44.4M | -68.14%12.32M | 224.44%17M | -62.77%8.75M | 122.48%6.32M | 122.00%51.38M | 112.10%38.68M | -154.44%-13.66M | -22.70%23.51M | -90.72%2.84M |
Operating gains losses | -464.80%-16.12M | -1,331.16%-10.95M | 115.79%51K | -170.87%-2M | -413.70%-3.23M | 538.93%4.42M | -90.04%889K | 89.84%-323K | 255.13%2.83M | 120.86%1.03M |
Depreciation and amortization | 3.62%163.64M | -1.01%40.31M | 12.81%43.07M | 0.86%39.83M | 2.26%40.43M | 8.50%157.93M | 11.68%40.72M | 5.74%38.18M | 6.90%39.49M | 9.68%39.54M |
Deferred tax | 173.50%9.43M | 4,470.91%7.54M | 236.48%9.99M | -323.41%-4.66M | -94.41%-3.44M | 104.66%3.45M | 100.18%165K | -55.93%2.97M | -56.41%2.09M | -131.42%-1.77M |
Other non cash items | 366.67%28.68M | -35.82%919K | -54.98%944K | 1,585.02%24.64M | 88.82%2.18M | 593.57%6.15M | 31.26%1.43M | 1,907.76%2.1M | 4,400.00%1.46M | 2,198.18%1.15M |
Change In working capital | 89.43%-42.63M | -111.19%-2.58M | 293.93%16.62M | 96.27%-15.45M | -154.33%-41.23M | -198.55%-403.29M | -94.99%23.03M | 386.35%4.22M | -1,411.52%-414.32M | 26.00%-16.21M |
-Change in receivables | 110.20%2.22M | 36.32%-14.03M | -167.87%-6.02M | -138.57%-18.31M | 296.84%40.57M | -73.03%-21.72M | -451.06%-22.03M | -141.90%-2.25M | -1.86%-7.67M | 260.06%10.22M |
-Change in inventory | 52.34%-4.75M | 116.14%1.47M | 61.44%4.86M | -224.79%-7.03M | 57.40%-4.05M | -169.05%-9.97M | -1,770.83%-9.11M | 2,695.69%3.01M | 20.17%5.64M | -202.03%-9.51M |
-Change in payables and accrued expense | 125.64%470K | -90.34%2.6M | 159.87%18.41M | 549.41%17.74M | -4,783.42%-38.29M | -108.45%-1.83M | -27.00%26.97M | -564.42%-30.75M | 123.55%2.73M | 92.36%-784K |
-Change in other current assets | -186.16%-3.24M | -41.83%5.14M | -140.67%-1.55M | -64.65%-4.36M | 60.19%-2.47M | 136.18%3.77M | 27.57%8.83M | 161.12%3.8M | -44.38%-2.65M | 33.00%-6.21M |
-Change in other current liabilities | -118.87%-3.79M | -277.16%-3.49M | 39.39%-180K | 134.29%48K | 52.69%-176K | -552.48%-1.73M | 16.46%-924K | -115.18%-297K | 63.82%-140K | -359.26%-372K |
-Change in other working capital | 90.98%-33.53M | -70.33%5.72M | -96.45%1.09M | 99.14%-3.54M | -285.38%-36.81M | -193.96%-371.79M | -95.41%19.29M | 438.04%30.7M | -3,736.11%-412.23M | -82.90%-9.55M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 251.74%224.16M | -50.75%55.72M | 132.87%97.45M | 118.21%61.3M | -71.36%9.7M | -153.15%-147.73M | 10.99%113.12M | -38.26%41.85M | -677.42%-336.58M | -32.21%33.87M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 16.71%-179M | -1.61%-65.87M | 30.06%-36.35M | 21.10%-41.92M | 22.49%-34.85M | -18.15%-214.91M | 9.64%-64.83M | -33.39%-51.98M | -48.80%-53.13M | -26.73%-44.97M |
Net PPE purchase and sale | 16.70%-179.07M | -1.61%-65.87M | 30.04%-36.39M | 21.10%-41.92M | 22.47%-34.89M | -17.87%-214.98M | 9.63%-64.83M | -33.37%-52.02M | -47.20%-53.13M | -26.60%-45M |
Net business purchase and sale | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net other investing changes | 7.25%74K | --0 | 0.00%37K | --0 | 15.63%37K | 115.63%69K | --0 | 8.82%37K | --0 | -49.21%32K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 16.71%-179M | -1.61%-65.87M | 30.06%-36.35M | 21.10%-41.92M | 22.49%-34.85M | -18.15%-214.91M | 9.64%-64.83M | -33.39%-51.98M | -48.80%-53.13M | -26.73%-44.97M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -119.01%-50.56M | -72.63%-6.55M | 23.16%-2.65M | -4,043.80%-29.42M | -104.36%-11.94M | 34.49%265.96M | -101.90%-3.79M | -763.50%-3.45M | -11.99%-710K | 61,105.79%273.92M |
Net issuance payments of debt | -103.95%-11.76M | -201.84%-3.77M | --0 | --0 | -102.66%-7.99M | 48.75%297.5M | -100.63%-1.25M | ---1.25M | --0 | --300M |
Net common stock issuance | -8.29%-4.43M | ---- | ---- | ---- | ---- | -940.46%-4.09M | ---- | ---- | ---- | ---- |
Net other financing activities | -25.23%-34.38M | 6.92%1.65M | -20.42%-2.65M | -4,043.80%-29.42M | 84.84%-3.96M | -1,387.11%-27.45M | 525.90%1.55M | -451.00%-2.2M | -11.99%-710K | -5,709.35%-26.08M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -119.01%-50.56M | -72.63%-6.55M | 23.16%-2.65M | -4,043.80%-29.42M | -104.36%-11.94M | 34.49%265.96M | -101.90%-3.79M | -763.50%-3.45M | -11.99%-710K | 61,105.79%273.92M |
Net cash flow | ||||||||||
Beginning cash position | -23.88%301.65M | 22.15%308.48M | -8.40%247.76M | -60.19%262.82M | -23.88%301.65M | 270.63%396.29M | 53.09%252.53M | 92.36%270.49M | 443.60%660.18M | 270.63%396.29M |
Current changes in cash | 94.42%-5.4M | -137.53%-16.7M | 530.30%58.45M | 97.43%-10.05M | -114.11%-37.1M | -132.90%-96.68M | -80.60%44.5M | -147.81%-13.58M | -1,879.00%-390.42M | 1,772.60%262.82M |
Effect of exchange rate changes | -953.02%-17.39M | -379.81%-12.92M | 152.07%2.28M | -787.93%-5.02M | -262.98%-1.74M | 145.76%2.04M | 142.82%4.62M | -7.44%-4.37M | 126.28%729K | 119.10%1.07M |
End cash Position | -7.55%278.87M | -7.55%278.87M | 22.15%308.48M | -8.40%247.76M | -60.19%262.82M | -23.88%301.65M | -23.88%301.65M | 53.09%252.53M | 92.36%270.49M | 443.60%660.18M |
Free cash flow | 112.43%45.09M | -121.02%-10.15M | 700.67%61.06M | 104.97%19.37M | -126.35%-25.19M | -479.47%-362.71M | 59.98%48.3M | -135.32%-10.17M | -1,856.00%-389.71M | -177.17%-11.13M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |